Similar articles

• Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.

  Elbl L, Hrstkova H, Tomaskova I, Michalek J. Elbl L, et al. Support Care Cancer. 2006 Feb;14(2):128-36. doi: 10.1007/s00520-005-0858-8. Epub 2005 Jul 21. Support Care Cancer. 2006. PMID: 16034614 Clinical Trial.
• [The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)].

  Sauer H. Sauer H. Strahlenther Onkol. 1997 Jan;173(1):51-2. doi: 10.1007/BF03039195. Strahlenther Onkol. 1997. PMID: 9082586 German. No abstract available.
• [Cardioxan--a drug of prevention of anthracycline-related cardiotoxicity in pediatric oncology].

  Kolygin BA. Kolygin BA. Vopr Onkol. 2002;48(1):110-2. Vopr Onkol. 2002. PMID: 12101558 Russian. No abstract available.
• [Prevention of anthracycline cardiotoxicity].

  Rossetti R. Rossetti R. Suppl Tumori. 2004 Jul-Aug;3(4):S117-9. Suppl Tumori. 2004. PMID: 15206234 Review. Italian. No abstract available.
• Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.

  Hellmann K. Hellmann K. Support Care Cancer. 1996 Jul;4(4):305-7. doi: 10.1007/BF01358885. Support Care Cancer. 1996. PMID: 8829310 Review.